Biological
IGSC 20%
IGSC 20% is a biological therapy with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Phase Distribution
Ph phase_4
1
33%
Ph phase_3
2
67%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 32 (66.7%)
Phase 41 (33.3%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_4
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
NCT04566692
completedphase_3
Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency
NCT02806986
completedphase_3
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
NCT02604810
Clinical Trials (3)
Showing 3 of 3 trials
NCT04566692Phase 4
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
NCT02806986Phase 3
Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency
NCT02604810Phase 3
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3